Alector, Inc. (NASDAQ:ALEC) Given Consensus Rating of "Hold" by Brokerages

Alector, Inc. (NASDAQ:ALEC - Get Free Report) has earned a consensus rating of "Hold" from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $4.00.

Separately, HC Wainwright boosted their price target on Alector from $7.00 to $10.00 and gave the company a "buy" rating in a report on Friday, May 9th.

Institutional Trading of Alector

Institutional investors have recently made changes to their positions in the stock. Northern Trust Corp grew its stake in shares of Alector by 5.6% during the 4th quarter. Northern Trust Corp now owns 759,874 shares of the company's stock valued at $1,436,000 after buying an additional 40,291 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Alector by 723.0% during the 4th quarter. BNP Paribas Financial Markets now owns 165,589 shares of the company's stock valued at $313,000 after buying an additional 145,469 shares during the period. Hsbc Holdings PLC grew its stake in shares of Alector by 26.1% during the 4th quarter. Hsbc Holdings PLC now owns 57,983 shares of the company's stock valued at $109,000 after buying an additional 12,004 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Alector by 12.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 160,570 shares of the company's stock worth $303,000 after purchasing an additional 17,509 shares during the period. Finally, Invesco Ltd. boosted its position in Alector by 27.7% during the 4th quarter. Invesco Ltd. now owns 47,985 shares of the company's stock worth $91,000 after purchasing an additional 10,405 shares during the period. 85.83% of the stock is owned by hedge funds and other institutional investors.

Alector Trading Up 5.6%

Shares of Alector stock opened at $1.52 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.34 and a quick ratio of 3.34. Alector has a 1 year low of $0.87 and a 1 year high of $6.78. The company has a market capitalization of $151.98 million, a P/E ratio of -1.21 and a beta of 0.74. The business has a 50 day moving average price of $1.36 and a 200 day moving average price of $1.46.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.